Nebivolol Bluepharma (Nebivolol Hydrochloride)

• Nebivolol is a selective β1‑adrenergic blocker used in the management of cardiovascular conditions.
• Hypertension: Lowers elevated blood pressure, reducing the risk of stroke and heart attack.
• Heart failure: Improves cardiac output and symptoms in patients with chronic heart failure.
• Left ventricular hypertrophy: May help reduce left‑ventricular mass associated with long‑term hypertension.

• Nebivolol Hydrochloride selectively antagonizes β1‑adrenergic receptors in cardiac tissue, decreasing heart rate and contractility. Concurrently, it stimulates endothelial nitric‑oxide synthase, leading to nitric‑oxide release and vasodilation. The combined effect reduces systemic vascular resistance and arterial pressure, providing an overall antihypertensive response without significant β2‑receptor blockade.

Nebivolol may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects

• Headache: mild to moderate discomfort.
• Dizziness or light‑headedness, especially after standing.
• Fatigue or general tiredness.
• Bradycardia: slower than normal heart rate.
• Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects

• Severe bradycardia or heart block requiring medical attention.
• Marked hypotension leading to fainting.
• Allergic reactions such as rash, itching, or swelling.
• Hepatic dysfunction or elevated liver enzymes.
• Acute heart failure exacerbation.

• When prescribing Nebivolol, clinicians should consider several precautionary measures to ensure patient safety.
• Monitor blood pressure: Verify adequate control without excessive lowering.
• Assess heart rate: Watch for bradycardia, especially in patients with conduction disorders.
• Use caution in asthma or chronic obstructive pulmonary disease: β1‑selectivity may still affect bronchial tone.
• Avoid abrupt discontinuation: Tapering may be needed to prevent rebound hypertension.
• Pregnancy and lactation: Safety not established; weigh benefits against potential risks.
• Store at ambient temperature: Keep in the original packaging, protect from moisture and direct sunlight.

Nebivolol can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Co‑administration with other beta‑blockers: risk of excessive bradycardia and hypotension.
• Combined with calcium‑channel blockers verapamil or diltiazem: increased risk of atrioventricular block.
• Potent CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may raise nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely)

• Diuretics: additive blood‑pressure‑lowering effect, monitor volume status.
• ACE inhibitors or ARBs: enhanced antihypertensive response, watch for hypotension.
• NSAIDs: may blunt the blood‑pressure‑lowering effect of nebivolol.
• Antidiabetic agents: possible alteration of glucose control, monitor blood sugar.